Search

Displaying results 1161 - 1170 of 10000 in total
  1. Drug

    Safinamide

    go.drugbank.com/drugs/DB06654
    ApprovedInvestigational

    Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.

  2. Drug

    Protein S human

    go.drugbank.com/drugs/DB13149
    ApprovedInvestigational

    Protein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties [A19561]. It serves as a negative feedback mechanism in the coagulation cascade.

    Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET
  3. Drug

    Lapatinib

    go.drugbank.com/drugs/DB01259
    ApprovedInvestigational

    It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. … Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer.

    Synonyms: N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
  4. Target

    Antigen peptide transporter 1

    go.drugbank.com/bio_entities/BE0003109
    TransporterHumans

    In complex with TAP2 mediates unidirectional translocation of peptide antigens from cytosol to endoplasmic reticulum (ER) for loading onto MHC class I (MHCI) molecules (PubMed:25377891, PubMed:25656091

    Synonyms: Peptide transporter involved in antigen processing 1
  5. Drug

    Chromic chloride

    go.drugbank.com/drugs/DB09129
    Approved

    Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).

    Mixtures: M T E 4 Concentrate Inj, Trace Elements Solution InjCategories: Compounds used in a research, industrial, or household setting
  6. Drug

    Coagulation factor X human

    go.drugbank.com/drugs/DB13148
    ApprovedInvestigational

    However its use is limited in the perioperative setting for the management of bleeding in major surgery in patients with moderate and severe hereditary Factor X deficiency. … While Factor X normally circulates in the plasma as inactive molecules, the activation of Factor X is involved in both the intrinsic and extrinsic coagulation pathways.

    Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET
  7. Drug

    Brinzolamide

    go.drugbank.com/drugs/DB01194
    Approved

    [L35310,L35315] In Europe, it was also approved as a combination product with timolol in 2008.[L35320] … [A2051] Brinzolamide was approved by the FDA in 1998 as a standalone product and in 2013 as a combination product with brimonidine tartrate.

  8. Drug

    Padimate O

    go.drugbank.com/drugs/DB11570
    Approved

    Padimate O is an active sunscreen agent in cosmetics and over-the-counter sunscreen drug products in concentrations up to 8%, as regulated by the FDA [L2153]. … It penetrates human skin, and is shown to induce non-ligatable strand breaks on DNA _in vitro_ and mutagenic effects on yeast i_n vivo_ [A32458].

    Mixtures: Skin Pro-tec II SPF-15, Dermatone SPF 23 Lips N Face ProtectorCategories: Compounds used in a research, industrial, or household setting
  9. Drug

    Tazobactam

    go.drugbank.com/drugs/DB01606
    ApprovedInvestigational

    and mortality in hospitalized patients. … Piperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014[FDA label], providing wider antibacterial coverage for gram-negative infections

    Mixtures: Zosyn in Galaxy Containers, Zosyn in Galaxy Containers
  10. Drug

    Gadoteridol

    go.drugbank.com/drugs/DB00597
    ApprovedInvestigational

    [A263076,A263081,L49871] It was 1 of the 3 macrocyclic gadolinium-based contrast agents (GBCAs) that was mandated by the EMA to replace linear gadolinium-based contrast agents due to concerns about retained … gadolinium in the brain.

    Categories: Compounds used in a research, industrial, or household setting